1. Scrip
  2. >>Therapy Areas
  3. >>Cardiovascular

Agennix expires

 
• By Sukaina Virji

At an extraordinary general meeting (EGM) on 22 May, Agennix shareholders voted in favor of the liquidation of the company. It will be dissolved by 31 May 2013, with liquidation slated to take at least a year following dissolution.

At an extraordinary general meeting (EGM) on 22 May, Agennix shareholders voted in favor of the liquidation of the company. It will be dissolved by 31 May 2013, with liquidation slated to take at least a year following dissolution.

Shareholders also voted to reduce the size of the supervisory board of Agennix from six to three members.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Cardiovascular

More from Therapeutic Category

Lyra Eyes US Filing For LYR-210 After Surprise ENLIGHTEN 2 Win

 
• By Sushmita Panda

In a turn of fortunes, Lyra Therapeutics has reported positive Phase III results for LYR-210 in chronic rhinosinusitis, boosting hopes for US approval. The company plans to submit an NDA and pursue further trials, but its cash position is precarious.

Ascletis Plans China Submission After Positive Denifanstat Phase III Acne Results

 
• By Sushmita Panda

Once-daily oral FASN inhibitor denifanstat meets all endpoints in a Chinese Phase III trial for moderate-to-severe acne, paving the way for a regulatory submission in China.

New Regenxbio DMD Data Support Gene Therapy Accelerated Approval

 
• By Joseph Haas

Regenxbio reported functional and biomarker data from an ongoing study of RGX-202, which it hopes to file for approval in Duchenne muscular dystrophy in 2026.